Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer

See allHide authors and affiliations

Science  03 Oct 2014:
Vol. 346, Issue 6205, pp. 85-89
DOI: 10.1126/science.1250255

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Mutant protein in tumors hits the DEK

Cancer genome sequencing projects have uncovered a multitude of mutations in human tumors. Understanding whether and how these mutations contribute to tumor development and progression could ultimately lead to new therapies. Theurillat et al. studied the protein product of a gene that is recurrently mutated in prostate cancer. Normally this protein helps attach a biochemical tag to cellular proteins that marks them for degradation. The new work shows that the tumor-associated mutant protein loses this tagging ability, which results in the stabilization of a handful of cellular proteins that would otherwise be degraded. One of the most intriguing of these proteins was DEK, which helps prostate cancer cells invade into surrounding tissue.

Science, this issue p. 85

View Full Text

Stay Connected to Science